로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Cell > TGF-beta 1 > CHEK-ATF145

Human TGF-beta R (Luc) HEK293 Reporter Cell

Order Now

  1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
  2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
  3. Comprehensive application data to support assay development and validation
  4. Full tracible record, stringent quality control and validated cell passage stability
  5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  6. Global commercial license assistance whenever regulatory filing is required
  • Description
    The Human TGF-beta R (Luc) HEK293 Reporter Cell was engineered to express Smad signaling response element driving luciferase expressing systems. When stimulated with TGF-beta (TGF-beta 1/2/3) protein, receptor-mediated signaling can drive Smad-mediated luminescence. Neutralization of biological effect of the ligand-receptor interaction by corresponding antibody results in a decrease in luminescence.
  • Application

    • Screen for neutralizing antibodies blocking the ligand-receptor interaction.

     TGF-beta 1 Assay Principles

  • Growth Properties
    Adherent
  • Selection Marker
    Puromycin (2 μg/mL)
  • Complete Growth Medium
    DMEM + 10% FBS
  • Freeze Medium
    Serum-free cell cryopreservation medium
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.

Application
 TGF-beta 1 APPLICATION

Inhibition of human TGF-beta 1 protein protein-induced reporter activity by a bifunctional fusion protein targeting TGF-beta and PD-L1.
This reporter cell was incubated with serial dilutions of the bifunctional fusion protein in the presence of human TGF-beta 1 protein (Cat. No. TG1-H4212) with a final concentration of 0.005 μg/mL. The EC50 of the bifunctional fusion protein (Bintrafusp alfa) is approximately 0.006323 μg/mL.

 TGF-beta 1 APPLICATION

Inhibition of human TGF-beta 2 protein protein-induced reporter activity by a bifunctional fusion protein targeting TGF-beta and PD-L1.
This reporter cell was incubated with serial dilutions of the bifunctional fusion protein in the presence of human TGF-beta 2 protein (Cat. No. TG2-H4215) with a final concentration of 0.003 μg/mL. The EC50 of the bifunctional fusion protein (Bintrafusp alfa) is approximately 1.06 μg/mL.

 TGF-beta 1 APPLICATION

Inhibition of human TGF-beta 3 protein protein-induced reporter activity by a bifunctional fusion protein targeting TGF-beta and PD-L1.
This reporter cell was incubated with serial dilutions of the bifunctional fusion protein in the presence of human TGF-beta 3 protein (Cat. No. TG3-H5213) with a final concentration of 0.002 μg/mL. The EC50 of the bifunctional fusion protein (Bintrafusp alfa) is approximately 0.0075 μg/mL.

Signaling Bioassay
 TGF-beta 1 SIGNALING

Response to human TGF-beta 1 protein (RLU).
The Human TGF-beta R (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TGF-beta 1 protein (Cat. No. TG1-H4212). The max induction fold was approximately 11.81.

 TGF-beta 1 SIGNALING

Response to human TGF-beta 1 protein (FOLD).
The Human TGF-beta R (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TGF-beta 1 protein (Cat. No. TG1-H4212). The max induction fold was approximately 11.81.

 TGF-beta 1 SIGNALING

Response to human TGF-beta 2 protein (RLU).
The Human TGF-beta R (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TGF-beta 2 protein (Cat. No. TG2-H4215). The max induction fold was approximately 12.15.

 TGF-beta 1 SIGNALING

Response to human TGF-beta 2 protein (FOLD).
The Human TGF-beta R (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TGF-beta 2 protein (Cat. No. TG2-H4215). The max induction fold was approximately 12.15.

 TGF-beta 1 SIGNALING

Response to human TGF-beta 3 protein (RLU).
The Human TGF-beta R (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TGF-beta 3 protein (Cat. No. TG3-H5213). The max induction fold was approximately 13.64.

 TGF-beta 1 SIGNALING

Response to human TGF-beta 3 protein (FOLD).
The Human TGF-beta R (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TGF-beta 3 protein (Cat. No. TG3-H5213). The max induction fold was approximately 13.64.

Please contact us if you are interested in related cell pool service.

  • Limited Use&License Disclosure

    BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

    1. If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
    2. Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
    3. This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use . You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    4. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    5. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    6. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.
  • Clinical and Translational Updates

Comments (0)


ETA of in-stock products: 2 business days

Price(USD) : $13150.00

Drug Candidate Licensing

more

Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:19 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop